Eisai Americas
Presença
Eisai é uma das ...
Eisai é uma empresa listada sob o símbolo 4523 (JP).
Eisai tem presença direta em 11 países.Eisai possui 12 subsidiárias incluindo EA Pharma, Eisai Americas e Eisai Australia.
Eles estão dentro:
Executivos
Veja o organograma con seus 27 executivos principais
Biografias mais buscadas da Eisai Americas
- Tatsuyuki Yasuno, President
- Paul Hawthorne, Executive Vice President, Purpose and Chief Busine...
- Charles Sabino, Vice President, Business Innovation & Transformati...
Criar um alerta
para seguir os movimentos de executivos da Eisai Americas.
Farmacêutica
Eisai possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Eisai Americas
- News & Press Releases | Eisai Inc.
- Eisai Mediaroom
- AB-related Paper Published in the American Scientific Journal Science
- AB-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE
- Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
- EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES’ NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER’S DISEASE
- Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
- EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES’ PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER’S DISEASE
- Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
- Eisai’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
- View more press releases Close
Redes sociais sobre Eisai Americas
- Eisai Americas na Wikipedia, Google News e Yahoo Finance
- Eisai Americas na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Tatsuyuki Yasuno 
Ligue para a Eisai Americas em +1 813 ...
